Dr. Vasiliki E. Kalodimou

Institute of Personalized Molecular Medicine at the Medical City Hospital, Philippines

Characterization of mesenchymal stem cells (MSCs) and their use in the treatment of COVID-19

Watch this presentation by Dr. Vasiliki E. Kalodimou, IASO Maternity-Pediatric and Research Hospital, titled: Characterization of mesenchymal stem cells (MSCs) and their use in the treatment of COVID-19. This keynote talk was presented at the SelectScience® Virtual Clinical Science Summit 2021.



LIKE 0


Dr. Vasiliki E. Kalodimou
Virtual summit

Dr. Vasiliki E. Kalodimou

Biography

Vasiliki E. Kalodimou is the collaborative partner for training and research for the Regenerative Medicine Program at the Institute of Personalized Molecular Medicine More

Dr. Vasiliki E. Kalodimou

Institute of Personalized Molecular Medicine at the Medical City Hospital, Philippines

Vasiliki E. Kalodimou is the collaborative partner for training and research for the Regenerative Medicine Program at the Institute of Personalized Molecular Medicine at the Medical City Hospital, Philippines, the Board/Committee on Research Ethics at the National Hellenic Research Foundation (Ε.Ι.Ε), she elected to serve as the Vice-Chair of the UEL Alumni Advisory Board, previously was the Director at the Flow Cytometry-Research and Regenerative Medicine Department of IASO Maternity-Pediatric and Research Hospital in Athens, Greece, as well as the CBB Director & Processing Facility Director at MedStem-Cryobanks of IASO. Before her current appointment, Kalodimou served as a hematology research associate at General University Hospital of Heraklion, Crete, and as an instructor at both the General University Hospital of Heraklion and the Ipokratios Medical-Technical Institute of Athens. Kalodimou received her degree in human physiology and master’s in human molecular genetics from the Imperial College University of Medicine in London, UK. She completed her Ph.D. at the University of Medicine in Athens, Greece, with an emphasis on stem cells and factors affecting their viability and absolute numbers. Since 2006, Dr. Kalodimou has studied and worked with stem cells from placenta, umbilical cord and adipose tissue, in everyday practice and their applications in regenerative medicine, clinical trials, medical tourism, and flow cytometry. She has also worked in the area of human genetics and population genetics, as well as cellular standards.